Key facts
- This page summarizes Russell J. Cox's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Jun 2023, 16:33.
Russell J. Cox - 22 Jun 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)
- Reporting relationship
- Director
- Issuer ticker
- SYRE
- Reported as of
- 22 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jun 2023, 16:33:37 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 06 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Alspaugh, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Russell J. Cox filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 30 Jun 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGLE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,950,000
- Change %
- Price
- $0.000000
- Shares after
- 1,950,000
- Date
- 22 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,950,000
- Exercise price
- $0.3000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
Footnote F2
The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.